These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2758729)

  • 1. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese.
    Horai Y; Nakano M; Ishizaki T; Ishikawa K; Zhou HH; Zhou BI; Liao CL; Zhang LM
    Clin Pharmacol Ther; 1989 Aug; 46(2):198-207. PubMed ID: 2758729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations.
    Sohn DR; Shin SG; Park CW; Kusaka M; Chiba K; Ishizaki T
    Br J Clin Pharmacol; 1991 Oct; 32(4):504-7. PubMed ID: 1958447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapsone N-acetylation, metoprolol alpha-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: a cocktail and extended phenotyping assessment trial.
    Setiabudy R; Kusaka M; Chiba K; Darmansjah I; Ishizaki T
    Clin Pharmacol Ther; 1994 Aug; 56(2):142-53. PubMed ID: 8062490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes.
    Koyama E; Sohn DR; Shin SG; Chiba K; Shin JG; Kim YH; Echizen H; Ishizaki T
    J Pharmacol Exp Ther; 1994 Nov; 271(2):860-7. PubMed ID: 7965806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
    Nakamura K; Goto F; Ray WA; McAllister CB; Jacqz E; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
    Nielsen KK; Brøsen K; Hansen MG; Gram LF
    Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
    Drøhse A; Bathum L; Brøsen K; Gram LF
    Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.
    Jurima M; Inaba T; Kadar D; Kalow W
    Br J Clin Pharmacol; 1985 Apr; 19(4):483-7. PubMed ID: 3994895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
    Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
    Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
    Wedlund PJ; Aslanian WS; McAllister CB; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1984 Dec; 36(6):773-80. PubMed ID: 6499356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms of debrisoquine and S-mephenytoin oxidation metabolism in Chinese populations: a meta-analysis.
    Xie HG; Xu ZH; Luo X; Huang SL; Zeng FD; Zhou HH
    Pharmacogenetics; 1996 Jun; 6(3):235-8. PubMed ID: 8807662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotyping polymorphic drug metabolism in the French Caucasian population.
    Jacqz E; Dulac H; Mathieu H
    Eur J Clin Pharmacol; 1988; 35(2):167-71. PubMed ID: 3191936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population.
    Xie HG; Huang SL; Xu ZH; Xiao ZS; He N; Zhou HH
    Pharmacogenetics; 1997 Apr; 7(2):115-9. PubMed ID: 9170148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.
    Sohn DR; Kusaka M; Ishizaki T; Shin SG; Jang IJ; Shin JG; Chiba K
    Clin Pharmacol Ther; 1992 Aug; 52(2):160-9. PubMed ID: 1505151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism.
    Guttendorf RJ; Britto M; Blouin RA; Foster TS; John W; Pittman KA; Wedlund PJ
    Br J Clin Pharmacol; 1990 Apr; 29(4):373-80. PubMed ID: 2328190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.
    Bertilsson L; Lou YQ; Du YL; Liu Y; Kuang TY; Liao XM; Wang KY; Reviriego J; Iselius L; Sjöqvist F
    Clin Pharmacol Ther; 1992 Apr; 51(4):388-97. PubMed ID: 1345344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.
    Inaba T; Jurima M; Nakano M; Kalow W
    Clin Pharmacol Ther; 1984 Nov; 36(5):670-6. PubMed ID: 6488688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.
    Schellens JH; van der Wart JH; Brugman M; Breimer DD
    J Pharmacol Exp Ther; 1989 May; 249(2):638-45. PubMed ID: 2724144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of a one-point (3-hour postdose) plasma metabolic ratio as a phenotyping test using metoprolol in two east Asian populations.
    Sohn DR; Kusaka M; Shin SG; Jang IJ; Chiba K; Ishizaki T
    Ther Drug Monit; 1992 Jun; 14(3):184-9. PubMed ID: 1412602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.